Side-by-side · Research reference
LiraglutidevsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedVerified14/45 cited
BPhase 2Reviewed10/41 cited
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
Liraglutide
Retatrutide
Primary target
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Downstream effect
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
—
Origin
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Antibody development
—
—
02Dosage Protocols
Parameter
Liraglutide
Retatrutide
Standard dose (weight, Saxenda)
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
—
Frequency
Once daily, same time each day
Once weekly
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
Evidence basis
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Phase 2 trial; Phase 3 ongoingJastreboff 2023
Duration
Indefinite for chronic indication
Indefinite for chronic indication (presumed)
Reconstitution
Pre-filled commercial pen (no reconstitution)
Investigational; not commercially available
Timing
Any time of day; consistent
Any time of day
04Side Effects & Safety
Parameter
Liraglutide
Retatrutide
GI symptoms
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023
Pancreatitis risk
Rare; discontinue if suspected
Class warning
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Class warning (presumed)
Hypoglycemia
Low risk as monotherapy; elevated with sulfonylureas / insulin
—
Pregnancy / OB
Contraindicated
Avoid (insufficient data)
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Absolute Contraindications
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
Liraglutide
Retatrutide
1. Reconstitution / device
Commercial pre-filled pen, no reconstitution required.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once daily, same time each day. Take with or without food.
Once weekly, same day.
4. Storage
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
Refrigerate 2–8 °C. Light-protected.
5. Needle
Pen-supplied 32G needle.
27–31G, 4–8 mm insulin syringe.